Epidemiological Aspects on Assessing and Treating Dyslipidemia in Type 1 Diabetes

– Studies from the Swedish National Diabetes Register

Akademisk avhandling

Som för avläggande av medicine doktorsexamen vid Sahlgrenska akademin, Göteborgs universitet kommer att offentligen försvaras i Hjärtats aula, Sahlgrenska Universitetssjukhuset, Göteborg, den 31 januari 2020, kl 09.00

av Christel Hero

Fakultetsopponent:
Professor Lisa Juntti-Berggren
Department of Molecular Medicine and Surgery, Karolinska institutet, Stockholm, Sverige

Avhandlingen baseras på följande delarbeten


Epidemiological Aspects on Assessing and Treating Dyslipidemia in Type 1 Diabetes
– Studies from the Swedish National Diabetes Register

Christel Hero
Department of Molecular and Clinical Medicine, Institute of Medicine at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Abstract

Background: Cardiovascular disease (CVD) is a major cause of shortened longevity in individuals with type 1 diabetes. Dyslipidemia is one of the important modifiable risk factors.

Aim: To investigate different aspects of dyslipidemia in type 1 diabetes: Assess available lipid variables as markers of CVD risk in type 1 diabetes. Investigate association between lipid-lowering therapy (LLT) and CVD in primary prevention. Assess the adherence to LLT and the associations between non-adherence and CVD risk. Investigate reasons for non-adherence from a sociodemographic perspective.

Method: Clinical characteristics and laboratory measures were collected from the Swedish National Diabetes Register alongside with data from several other Swedish registries on health and socioeconomy. In study I Cox regression analyses were performed to assess LDL cholesterol and total cholesterol to HDL-cholesterol ratio as predictors of CVD in type 1 diabetes. In study II we investigated the association between primary prevention with LLT and the risk of CVD in 24,230 individuals with type 1 diabetes applying propensity scores to balance the groups. In study III and IV we utilized the Swedish Prescribed Drug Register to investigate adherence and non-adherence in 6,192 individuals with type 1 diabetes and novel users of LLT, in the context of CVD and socioeconomy.

Results: Total-cholesterol to HDL-cholesterol ratio was a better predictor for cardiovascular risk in primary prevention than LDL-cholesterol, with a 12% elevated risk of CVD per 1 unit increase in the ratio.

Individuals with type 1 diabetes and no history of CVD had a 22–44% lower risk of CVD and cardiovascular death when on LLT compared to the untreated individuals. High adherence to LLT was associated with a 22% lower risk of non-fatal CVD compared to lower adherence. Individuals discontinuing LLT within 18 months had a 43% higher risk of non-fatal CVD. Lower adherence was associated with male gender, young age, marital status and country of birth.

Conclusion: The observational data from these presented studies emphasize the importance of regularly assessing and treating dyslipidemia in individuals with type 1 diabetes in order to achieve full cardioprotective treatment and lessen the cardiovascular burden in the type 1 diabetes population.

Keywords: Type 1 diabetes, LDL cholesterol, lipid-lowering treatment, cardiovascular disease, adherence, discontinuation, socioeconomic status